RECURSION PHARMACEUTICALS, INC.
No SEC Form 4 filings for $RXRX in the last 30 days.
The article discusses Recursion Pharmaceuticals (RXRX) trading at a 52-week low and claims the stock may be oversold, but it provides no specific RXRX financial figures. It also cites comments from Bill Gates, Larry Ellison/Oracle, and Elon Musk on AI’s potential, and promotes a paid newsletter offering “underdog” stock picks, including a $3 stock with claimed “400% upside.”
KeyCorp initiated its Q4 2026 EPS estimate for Recursion Pharmaceuticals (NASDAQ:RXRX) at ($0.20) per share, with full-year 2026 and 2027 estimates at ($1.05) and ($0.90) respectively. This follows Recursion's Q1 earnings report where EPS of ($0.22) beat expectations, but revenue of $6.47 million significantly missed the forecast and declined year-over-year. The stock holds an average "Hold" rating from analysts with an $8.10 target price, and insider selling has been noted while the stock trades near its 52-week low.
As Wall Street expresses concerns about the high valuations of large-cap AI stocks and the Nasdaq-100, smaller AI companies are gaining attention for their potential for significant growth. This article highlights three small-cap AI plays—Arista Networks (ANET), Innodata (INOD), and Recursion Pharmaceuticals (RXRX)—noting their distinct advantages in the evolving AI landscape, from specialized infrastructure to data engineering and drug discovery. While offering asymmetric upside, investors are cautioned about the inherent volatility and risk associated with small-cap investments.
